Virtually all adults with Down syndrome (DS) show the neuropathological changes of
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …

Abstract Introduction Adults with Down syndrome (DS) are at exceptionally high risk for
Alzheimer's disease (AD), with virtually all individuals developing key neuropathological …

Abstract Introduction Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD)
neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would …

Introduction Microglial cells play an important role in the development of Alzheimer's
disease (AD). People with Down syndrome (DS) inevitably develop AD neuropathology …

Mitochondrial dysfunctions have been described in Down syndrome (DS) caused by either
partial or full trisomy of chromosome 21 (HSA21). Mitochondria play a crucial role in various …

Although Alzheimer's disease (AD) is traditionally viewed as a central nervous system
disorder driven by the cerebral accumulation of toxic beta-amyloid (Aβ) peptide, new …

An important line of postgenomic research seeks to understand how genetic factors can
influence epigenetic patterning. Here we review epigenetic effects of chromosomal …

The present study aims to investigate the cognition‐enhancing effect of 3, 14, 19‐Triacetyl
andrographolide (ADA) on learning and memory deficits in 3× Tg‐AD mice and to explore its …

Down syndrome (DS) is a common genetic condition caused by the presence of three
copies of chromosome 21 (trisomy 21). This greatly increases the risk of Alzheimer disease …

Background Obesity in adults without Down syndrome is associated with an adverse
metabolic profile including high prevalence of pre‐diabetes and diabetes, high levels of …